BioDelivery Sciences International Inc. (NASDAQ:BDSI) – William Blair reduced their FY2016 earnings estimates for BioDelivery Sciences International in a research note issued on Wednesday. William Blair analyst T. Lugo now expects that the firm will earn ($1.30) per share for the year, down from their previous forecast of ($1.16). William Blair also issued estimates for BioDelivery Sciences International’s Q4 2016 earnings at ($0.29) EPS and FY2017 earnings at ($1.02) EPS.

A number of other analysts have also weighed in on BDSI. Roth Capital set a $7.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 30th. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, July 27th. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a research note on Tuesday, September 20th. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a research note on Wednesday, August 10th. Finally, Piper Jaffray Cos. restated a “sell” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research note on Wednesday, August 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $6.57.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) opened at 1.90 on Monday. BioDelivery Sciences International has a 12 month low of $1.70 and a 12 month high of $6.40. The stock’s market cap is $101.91 million. The firm has a 50-day moving average price of $2.33 and a 200-day moving average price of $2.42.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.04. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. The business earned $3.60 million during the quarter, compared to analysts’ expectations of $3.58 million. During the same period last year, the firm posted ($0.39) EPS. BioDelivery Sciences International’s quarterly revenue was up 200.0% compared to the same quarter last year.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of BioDelivery Sciences International by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 62,945 shares of the specialty pharmaceutical company’s stock valued at $170,000 after buying an additional 5,677 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in shares of BioDelivery Sciences International by 12.0% in the second quarter. Janney Montgomery Scott LLC now owns 61,300 shares of the specialty pharmaceutical company’s stock valued at $294,000 after buying an additional 6,550 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of BioDelivery Sciences International by 1.2% in the second quarter. Parametric Portfolio Associates LLC now owns 807,097 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after buying an additional 9,727 shares in the last quarter. NEXT Financial Group Inc increased its stake in shares of BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 14,850 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of BioDelivery Sciences International by 2.2% in the third quarter. Bank of Montreal Can now owns 713,805 shares of the specialty pharmaceutical company’s stock valued at $1,927,000 after buying an additional 15,515 shares in the last quarter. 60.83% of the stock is owned by institutional investors and hedge funds.

In other BioDelivery Sciences International news, insider Niraj Vasisht sold 47,000 shares of the firm’s stock in a transaction dated Friday, September 23rd. The stock was sold at an average price of $2.43, for a total value of $114,210.00. Following the completion of the sale, the insider now owns 73,081 shares of the company’s stock, valued at $177,586.83. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Paolantonio Ernest Robert De sold 14,800 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $2.44, for a total value of $36,112.00. Following the completion of the sale, the chief financial officer now directly owns 14,866 shares of the company’s stock, valued at approximately $36,273.04. The disclosure for this sale can be found here. Corporate insiders own 9.00% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.